Drug Trial Radar · NCT02308501
A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy
Last checked: Nov 20, 2026Latest source record: Mar 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Dec 2014
Primary completion
Feb 2015
Study completion Feb 2015
Sponsor
- Lead sponsor
- ORA, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 4, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft ® as Measured by In-Vivo Confocal Microscopy
Conditions
- Allergic Conjunctivitis
Interventions
Lastacaft ®Drug
Tears Naturale ® (Placebo)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Conjunctival Inflammation at 1 Hour (+30 Minutes) Post CAC on Day 1Time frame: 1 hour (+30 minutes) post CAC on Day 1
- Conjunctival Inflammation 1 Hour (+30 Minutes) Post CAC on Day 2Time frame: 1 hour (+30 minutes) post CAC on Day 2
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.